Bulbine natalensis to Improve Testosterone

Evidence Review created on 08/09/2026 using AI4L / Grok 4

Also known as: Bulbine latifolia, Ibhucu, Rooiwortel, Ingcelwane, Broad-leaved Bulbine, Geelkopieva, ProLensis

Motivation

Bulbine natalensis (also called Bulbine latifolia) is a South African succulent whose stem extract has entered male hormone and performance markets as a plant-based testosterone support. Traditional use as a male vitality tonic, plus rat work showing large rises in blood and testicular testosterone at mid-range doses, has driven consumer interest among people who want to raise testosterone without prescription hormone therapy.

Context for that interest includes parallel rises in luteinizing hormone and follicle-stimulating hormone in animals, improved mating behavior in the same models, and a single short human safety trial of a branded extract that did not show clinically important blood, liver, kidney, or heart-marker harm over four weeks. At the same time, the same dose band that raised testosterone in rats altered liver and kidney markers and tissue structure, and cell studies flag interaction risk with drugs handled by major liver enzymes.

This review examines the animal testosterone and sexual-behavior data, the limited human safety evidence, proposed mechanisms, dose patterns used in research and commerce, organ and drug-interaction risks, and practical monitoring for longevity-oriented adults weighing this herb as a testosterone-support option.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article for Bulbine natalensis (or its synonym Bulbine latifolia) was found.

Examine

Bulbine natalensis

Concise evidence summary: rat work shows strong testosterone gains with concurrent organ-toxicity signals at the same doses; human dose estimates (~8 mg/kg extract) and the single industry-linked 650 mg/day safety trial are laid out clearly.

ConsumerLab

No ConsumerLab article or product review for Bulbine natalensis was found.

Systematic Reviews

No systematic reviews or meta-analyses for Bulbine natalensis were found on PubMed as of August 9, 2026.

Mechanism of Action

Proposed androgen effects rest almost entirely on rodent pharmacology of aqueous stem extract.

Gonadotropin–testicular axis: Mid-range oral doses (25–50 mg/kg in rats) raise serum luteinizing hormone (LH; pituitary signal that drives testicular testosterone) and follicle-stimulating hormone (FSH; supports sperm-lineage cells), with parallel rises in testicular and circulating testosterone. Higher dose (100 mg/kg) often blunts or delays these gains, consistent with a mid-range peak rather than simple linear stimulation.
Local testicular anabolism: Increases in testicular–body weight ratio, testicular protein, glycogen, sialic acid (a sugar-related gland marker), cholesterol, and acid/alkaline phosphatase activities have been read as support for higher local androgen production and gland activity.
Phytochemical drivers (proposed): Saponins (soap-like plant compounds), alkaloids (nitrogen-containing plant compounds), tannins (astringent plant polyphenols), cardiac glycosides (heart-active plant sugars), and anthraquinones (including knipholone-type plant pigments) are present in stem extracts. Saponins are often hypothesized to support the body’s own androgen production; alkaloids may influence local blood flow. Causal assignment of any single constituent to the testosterone rise has not been proven in living organisms.
Estradiol: Male rats show reduced serum estradiol at several doses, which would raise the testosterone-to-estrogen ratio if replicated in humans—still untested clinically.
Drug-metabolizing systems (interaction mechanism, not testosterone mechanism): Methanol-based extract and knipholones activate the pregnane X receptor (PXR; nuclear sensor that increases production of drug-metabolizing enzymes), induce CYP3A4 (major liver enzyme that breaks down many drugs) and CYP2C9 (liver enzyme that metabolizes warfarin and many non-steroidal anti-inflammatory drugs (NSAIDs)) expression, and block CYP2C9 enzyme activity in cell models. Separate work shows modulation of aryl hydrocarbon receptor (AhR; a cellular sensor that regulates certain detox and drug-metabolizing pathways), CYP1A2 (liver enzyme for caffeine and some drug pathways), CYP2B6 (liver enzyme for several antidepressants and prodrugs), and P-glycoprotein (P-gp; drug export pump). These pathways matter for herb–drug interaction risk more than for androgen output.
Drug handling in the body: Human half-life, oral bioavailability, tissue distribution, and metabolite profile of stem extract or knipholones are not established. Product labels rarely state standardized markers beyond crude extract weight.

Historical Context & Evolution

Traditional use: B. natalensis / B. latifolia is a southern African succulent (Asphodelaceae). Leaf sap has long been applied to wounds, burns, rashes, and skin infections; root infusions have been used for gastrointestinal and rheumatic complaints; stem preparations appear in Zulu and related traditional medicine as male sexual tonics (local names include ibhucu, ingcelwane, rooiwortel).
Entry into optimization markets: After the 2008–2010 University of Fort Hare rat series (sexual behavior, reproductive toxicity, anabolic/androgenic endpoints, liver/kidney indices, lipids), Western bodybuilding and natural testosterone-support channels popularized the herb. Branded extracts (e.g., ProLensis™) were positioned for sexual-behavior and muscle-support use.
Safety and interaction layer: The same lab reported liver and kidney marker and tissue-structure changes at androgen-active doses (2009). A 2012 industry-linked, placebo-controlled human safety abstract (28 days, ~650 mg/day) found no clinically meaningful laboratory harm in healthy men—efficacy endpoints were not published. 2020–2022 National Center for Natural Products Research work on CYP/PXR/P-gp expanded the interaction caution. Taxonomy notes increasingly treat Bulbine natalensis Baker as synonymous with Bulbine latifolia (L.f.) Spreng.

Scientific opinion has not “settled”: animal androgen efficacy has not been repeated in independent labs at scale, human hormone trials are absent, and risk communication still splits between marketers citing the safety abstract and toxicology researchers citing rodent organ data.

Expected Benefits

Low 🟩

Raised serum and testicular testosterone (animal)

Multiple controlled rat studies from one research group report significant increases in circulating and testicular testosterone after oral aqueous stem extract, most pronounced near 50 mg/kg body weight, with weaker or delayed responses at 100 mg/kg. Parallel rises in LH and FSH support a central (pituitary) plus local testicular contribution. No randomized human trial has measured testosterone change; magnitude in people is unknown.

Magnitude: Not quantified in available studies.

Enhanced male sexual behavior and mating success (animal)

At 25–50 mg/kg, rats showed more mounting and mating attempts, longer time to ejaculation, more penile reflexes, and improved mating/fertility success indices, with shorter latencies to initiate sex. The 100 mg/kg dose reversed many of these patterns. Human sexual-function randomized controlled trials (RCTs) are lacking.

Magnitude: Not quantified in available studies.

Increased testicular mass and anabolic testicular markers (animal)

Testicular–body weight ratio and testicular protein, glycogen, sialic acid (a sugar-related gland marker), cholesterol, and phosphatase activities rose with androgen-active doses, interpreted as anabolic/androgenic tissue activity. Translation to lean mass or strength in humans has not been tested.

Magnitude: Not quantified in available studies.

Lower circulating estradiol (animal)

Male rats given stem extract showed reduced serum estradiol across tested doses, which would theoretically improve androgen-to-estrogen balance. Human estradiol data after B. natalensis are not available.

Magnitude: Not quantified in available studies.

Speculative 🟨

Muscle strength, body composition, or marketed anabolic physique effects

Marketing often implies anabolic outcomes from the testosterone signal. No controlled human or robust animal body-composition trials establish this; any such benefit remains mechanistic speculation only.

Cognitive or energy benefits secondary to androgen change

Anecdotes describe higher energy or motivation. Controlled cognitive endpoints in humans have not been published.

Benefit-Modifying Factors

Baseline androgen status: Individuals with low-normal or clinically low testosterone may have more room to show a measurable rise if the animal gonadotropin mechanism translates; users with already-normal sex-hormone status may see smaller relative change. This is extrapolated, not demonstrated.
Dose window: Animal data show a mid-range peak—mid doses outperform both low and high. Intakes above that mid-range peak may blunt sexual behavior and hormone gains rather than amplify them.
Sex: Nearly all androgen and sexual-behavior data are in male animals. Female reproductive outcomes at 25–50 mg/kg were largely unaltered except higher early pregnancy loss index (early embryo/fetal loss rate) at 100 mg/kg; use in females to raise testosterone is not supported by efficacy data.
Age: Trials and animal work used young adult males. Older adults with multiple chronic conditions, many concurrent medications, or reduced liver/kidney reserve face higher interaction and organ-stress risk; benefit is unstudied in aging cohorts.
Liver and kidney baseline: Pre-existing enzyme elevation or reduced filtration may both limit safe exposure and confound monitoring; benefit pursuit is higher-risk in this group.
Extraction and product identity: Aqueous stem extract in academic work may not match commercial “10:1” or proprietary extracts (e.g., ProLensis™). Marker standardization (knipholones, saponins) is inconsistent, so benefit transfer across products is uncertain.

Potential Risks & Side Effects

Medium 🟥 🟥

Liver and kidney marker and tissue-structure stress (animal; human short-term labs more reassuring) ⚠️ Conflicted

In male rats, 50–100 mg/kg stem extract for 14 days raised liver enzymes (ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase), GGT (gamma-glutamyl transferase)) and total bilirubin, lowered albumin, and produced mild disruption of normal liver and kidney tissue structure; authors concluded the extract is not fully “safe” as an oral remedy and is toxic on some laboratory measures but not others. By contrast, a 28-day double-blind trial in 36 healthy men (325 mg twice daily ProLensis™) found only small shifts that were not clinically important in alkaline phosphatase and creatinine, with other liver, kidney, blood-cell, and heart/blood-pressure markers similar to placebo. The animal signal and human short-term abstract therefore conflict in severity; longer human exposure is unstudied.

Magnitude: Rat enzyme/tissue-structure changes at androgen-active doses; human 28-day panel within normal limits in one small industry-linked study.

Low 🟥

Adverse lipid shift (animal)

Aqueous stem extract raised serum cholesterol and triglycerides and lowered HDL (high-density lipoprotein, the “protective” cholesterol fraction), worsening a cholesterol-related heart-disease risk index after two weeks in rats. Human lipid effects are unknown.

Magnitude: Not quantified in available studies.

White-cell and blood-cell shifts (animal)

Localized changes in white-cell counts and in the mix of white-cell types were reported without major red-cell toxicity. Clinical relevance in humans is unclear; the 28-day human safety panel did not flag blood-cell harm.

Magnitude: Not quantified in available studies.

High-dose behavioral suppression (animal)

At 100 mg/kg, sexual-behavior indices and some hormone responses moved opposite to the mid-dose pattern, sometimes described as calming or sedation-like. Exceeding commercial doses could theoretically blunt rather than improve libido.

Magnitude: Not quantified in available studies.

Herb–drug interaction via CYP enzymes and drug-export pumps (cell models)

Extract and knipholones induce CYP3A4/CYP2C9 via PXR, inhibit CYP2C9 activity, and modulate CYP1A2, CYP2B6, AhR, and P-gp. Clinical interaction studies in humans are absent; risk is inferred from cell systems.

Magnitude: Not quantified in available studies.

Heavy-metal contamination of crude market material

Analyses of some South African open-market medicinal plants, including material sold as this species, have reported elevated aluminum and iron. Contaminated products can add organ burden independent of intrinsic phytochemistry; risk is product-dependent.

Magnitude: Not quantified in available studies.

Early pregnancy loss risk at high dose (animal)

In reproductive toxicity research, female rats at 100 mg/kg showed a higher early pregnancy loss index, while 25–50 mg/kg did not clearly impair female reproductive indices. Human pregnancy data are absent; the high-dose animal signal supports treating pregnancy and attempted conception as high-caution settings rather than proven safety at any commercial dose.

Magnitude: Higher early pregnancy loss index at 100 mg/kg in female rats; lower doses without clear female reproductive impairment in the same study.

Speculative 🟨

Aggression, acne, or testicular discomfort (anecdotal / uncontrolled report)

Podcast and forum reports (including high-profile uncontrolled personal use reports) describe short-term subjective “androgen” effects followed by irritability, skin changes, or testicular pain. These are uncontrolled and may reflect product tampering, dose extremes, or unrelated factors; they are not confirmed in trials.

Risk-Modifying Factors

Baseline liver and kidney function: Elevated ALT/AST/GGT or reduced eGFR (estimated glomerular filtration rate, a kidney filtration score) magnifies concern from the rodent liver and kidney signal and complicates interpretation of on-treatment labs.
Genetic polymorphisms affecting CYP enzymes: Variants that alter CYP3A4 or CYP2C9 activity can change how strongly induction or inhibition of those pathways affects co-administered drugs; no validated gene-based dosing algorithm exists for this herb, but genetically low or high enzyme activity may amplify theoretical interaction risk.
Many concurrent medications and CYP substrates: Users on CYP3A4 or CYP2C9 substrates with a small margin between effective and toxic dose (e.g., certain statins, warfarin/S-warfarin pathway drugs, some calcium-channel blockers, anxiolytics (anxiety-relief medications)) face theoretical interaction risk from induction/inhibition patterns seen in cell models.
Sex: Male-focused marketing and data dominate; females lack efficacy evidence and carry pregnancy-related caution at high animal doses.
Age and multiple chronic conditions: Older adults more often take interacting drugs and have reduced organ reserve; risk–benefit is less favorable without monitoring.
Dose and duration: Risk signals in rats cluster at ≥50 mg/kg and multi-week continuous use. Longer or higher human exposure is not studied.
Product quality: Unstandardized powders and open-market roots raise contamination and misidentification risk relative to identity-tested extracts.

Key Interactions & Contraindications

Prescription CYP3A4 substrates (e.g., midazolam, certain statins such as simvastatin/atorvastatin, some calcium-channel blockers, calcineurin inhibitors (immune-suppressing drugs that block a cell-signaling enzyme)): Caution — cell-model induction may lower drug levels (loss of drug effect) or, with mixed induction/inhibition timing, produce unpredictable exposure. Mitigate by avoiding combination or involving a clinician for level/effect monitoring.
Prescription CYP2C9 substrates (e.g., warfarin, phenytoin, some NSAIDs such as celecoxib, sulfonylureas (diabetes drugs that lower blood sugar)): Caution — strong blocking of enzyme activity plus increases in how much enzyme is made, seen in cell models, may raise or destabilize drug levels (bleeding risk with warfarin). Mitigate by avoiding combination or intensifying INR (international normalized ratio, a clotting-time measure used on warfarin)/glucose/drug-level checks.
CYP1A2 / CYP2B6 / P-gp substrates (e.g., clopidogrel activation pathways, some antidepressants, digoxin as P-gp substrate): Caution — additional modulation reported in cell models; clinical magnitude unknown.
Digoxin and cardiac glycosides: Caution — stem material may contain cardiac-glycoside-like constituents; additive toxicity risk. Avoid concurrent use with digoxin.
Anticoagulant / antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin, etc.): Caution — leaf material has been associated with slowed clotting in early lab tests; bleeding risk may rise. Stop well before elective surgery (commonly cited window ≥2 weeks for herbs with antiplatelet signals).
Added testosterone or potent androgenic agents: Caution — theoretical additive androgenic adverse effects (hematocrit, acne, mood, suppression patterns) if the herb truly raises the body’s own testosterone.
Other testosterone-support combinations (e.g., high-dose fenugreek, tongkat ali, fadogia, aromatase inhibitors (drugs that block conversion of androgens to estrogen)): Caution — additive endocrine or organ-stress effects are unstudied; multi-agent regimens make attribution of laboratory changes to a single agent difficult.
Populations who should avoid (or use only under close medical oversight):
- Pregnancy and attempted conception (female): possibly unsafe; high-dose animal early-pregnancy-loss signal
- Breastfeeding: insufficient data — avoid
- Active liver disease, unexplained enzyme elevation, or advanced chronic kidney disease
- Planned surgery within 2 weeks (bleeding caution for leaf-containing products)
- Children and adolescents
- Anyone unable or unwilling to obtain baseline and follow-up hormone and organ labs

Risk Mitigation Strategies

Baseline and interval labs: Obtain liver enzymes (ALT, AST, GGT, ALP), bilirubin, albumin, creatinine/eGFR, fasting lipids, CBC (complete blood count), total and free testosterone, SHBG (sex hormone–binding globulin), estradiol, LH, and FSH before starting; repeat at 2–4 weeks and after any dose change. Mitigates silent liver, kidney, or lipid injury and documents whether testosterone actually moves.
Conservative dose and product choice: Prefer identity-tested extracts with stated plant part (stem) and batch testing over bulk “root powder” from open markets. Stay near the only human-studied total daily amount (~650 mg/day split) rather than multi-gram raw-plant extrapolations. Mitigates contamination and dose-related toxicity risk.
Time-limited courses with treatment-free intervals: Limit continuous use (e.g., 4–8 weeks) then reassess labs and symptoms after discontinuation. Mitigates cumulative organ stress suggested by multi-week rat tissue-structure findings.
Drug reconciliation: Review all prescriptions and OTC (over-the-counter) agents for CYP3A4/2C9/1A2/P-gp involvement before combining; do not co-start with warfarin or digoxin. Mitigates interaction-driven adverse events.
Symptom-based stopping rules: Discontinue for right-upper-quadrant pain, dark urine, jaundice, marked edema, unusual bruising/bleeding, severe irritability, or testicular pain; seek care and labs. Mitigates progression of organ or endocrine adverse effects.
Avoid concurrent use with other liver-damaging or unstandardized androgenic herbs: Reduces additive liver burden and mixed, hard-to-interpret monitoring.

Therapeutic Protocol

No consensus clinical protocol exists; the following synthesizes animal dose-finding, the single human safety regimen, and Examine dose conversions—not a standard of care.

Human-studied safety regimen (ProLensis™): 325 mg in the morning and 325 mg about six hours later (650 mg/day total) for 28 days in healthy men—safety endpoints only; efficacy not reported.
Examine-style extract estimate from rat 50 mg/kg: Roughly 8 mg/kg body weight of a concentrated extract (~550 mg for ~68 kg; ~730 mg for ~91 kg), sometimes aligned with commercial 10:1 extracts. Raw unextracted plant would require substantially higher mass.
Commercial practice: Many capsules provide ~300–400 mg extract per serving, often marketed 1–2 times daily. Labels vary widely; marker standardization is uncommon.
Timing: Split dosing (morning + afternoon) matches the human safety trial. Food effect is unstudied; consistent timing aids interpretation of labs.
Half-life and dose splitting: Human half-life unknown. Split dosing is practical for steady exposure and GI (gastrointestinal) tolerance, not proven by human drug-level studies.
Sex differences: Efficacy protocol is male-oriented; female protocols for testosterone elevation are not evidence-based.
Age: No dosing data in older adults; older users warrant lower starting exposure and tighter lab follow-up.
Genetics: No validated gene-based dose algorithm. Variants affecting CYP3A4/CYP2C9 activity may alter interaction risk more than primary testosterone response.
Baseline hormones and organ function: Confirm true hypogonadal (low sex-hormone) or low-normal status and acceptable liver/kidney labs before attributing any later change to the herb.
Competing approaches: Lifestyle foundations (sleep, resistance training, body-fat management, alcohol limitation) and, where indicated, medically supervised testosterone therapy remain the better-supported paths for raising testosterone; B. natalensis is an unproven add-on, not a substitute established by RCTs.

Discontinuation & Cycling

Duration intent: Not characterized as lifelong therapy. Evidence and risk profile favor time-limited courses of use with lab-defined stop/continue decisions.
Withdrawal: No classic hormone-withdrawal syndrome described. If the body’s own LH/FSH were stimulated, stopping could allow return toward baseline testosterone over days to weeks (unmeasured in humans).
Tapering: Not required by known receptor-sensitivity data; abrupt cessation is typical. Taper only if feeling agitated or if combined with other hormonal agents under clinician advice.
Cycling: Common in consumer supplement practice (e.g., 4–8 weeks on, several weeks off) to limit possible accumulation of liver and kidney burden. Cycle structure is based on practice, not proven in trials.
Restarting after a break: Only after normalized labs and clear goal metrics; repeated courses without monitoring are higher risk.

Sourcing and Quality

Plant identity: Prefer products specifying Bulbine natalensis / Bulbine latifolia, stem (or clearly stated plant part), and Latin scientific name. Synonym confusion and look-alike Bulbine species occur in trade.
Extract definition: Look for extraction ratio, solvent, and—if available—knipholone or other anthraquinone marker assays (UHPLC (ultra-high-performance liquid chromatography) methods exist in the analytical literature). Multi-ingredient “proprietary blend” products often underdose the herb.
Third-party testing: Certificates for identity, microbial limits, pesticides, and heavy metals (Al, Fe, Pb, As, Cd, Hg) address documented contamination concerns in some African market botanicals.
Branded examples: ProLensis™ is the extract named in the published human safety abstract; availability and current composition should be verified per lot. Other reputable specialty-herb suppliers may offer single-ingredient capsules—evaluate COAs (certificates of analysis) rather than brand name alone.
Avoid: Unlabeled bulk powders from open markets; multi-ingredient testosterone-support blends that obscure the individual dose; products making disease-treatment claims.

Practical Considerations

Time to effect: Animal hormone and behavior changes appeared within days to two weeks. Human testosterone onset is unknown; any individual trial of the intervention should not be judged before a 2–4 week laboratory reassessment.
Common pitfalls: Assuming rat multi-fold testosterone rises apply to humans; using multi-gram raw-plant doses scaled 1:1 from mg/kg rat data without BSA (body surface area) conversion; combining with other liver-damaging agents; skipping liver labs; trusting untested open-market root material.
Regulatory status: Sold as a dietary supplement / traditional herbal product in various markets, not FDA (U.S. Food and Drug Administration)-approved to treat hypogonadism (clinically low sex-hormone production) or any disease. Quality and claim review are limited compared with prescription androgens.
Cost and access: Single-ingredient capsules are generally inexpensive relative to clinic TRT (testosterone replacement therapy), but low-cost products may lack identity testing—limited value if contaminated or without verified active content. Institutional payers (insurers, national health systems) typically reimburse medically supervised testosterone therapy when diagnostic criteria are met and do not cover unproven herbal extracts, which can channel guideline attention and research funding toward reimbursable prescription pathways rather than independent efficacy trials of this herb.

Interaction with Foundational Habits

Sleep: Direction unclear (none established). Poor sleep independently lowers testosterone; any herb trial that disrupts sleep (stimulant or anxiety effects in sensitive users) would blunt net androgen goals. Practical: dose earlier in the day if sleep is easily disrupted.
Nutrition: Indirect, potentially antagonistic if animal lipid shifts translate (higher TG (triglycerides)/cholesterol, lower HDL). Emphasize fiber-rich patterns with more unsaturated fats and recheck lipids. No specific food cofactor is proven to enhance absorption.
Exercise: Indirect / potentially potentiating — strengthening in theory if testosterone rises and training is progressive resistance work; unproven. Avoid attributing strength gains to the herb without a controlled baseline. No evidence it blunts muscle growth.
Stress management: Indirect / potentially blunting — chronic psychological stress elevates cortisol and can suppress the HPG axis (hypothalamic–pituitary–gonadal pathway controlling testosterone). Herb use does not replace sleep and basic stress-management habits; concurrent high stress may mask any modest testosterone signal.

Monitoring Protocol & Defining Success

Baseline testing before the first dose establishes hormones, organ safety, and lipids. Ongoing monitoring at 2–4 weeks, again near 8 weeks if continued, then every 3 months during any extended use—or sooner if symptoms arise.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Total testosterone	Adult male functional targets often ~500–900 ng/dL (lab-specific)	Primary efficacy endpoint for this intervention	Conventional adult male reference often ~300–1000 ng/dL; functional target emphasizes mid–upper range. Morning draw (7–10 a.m.); repeat if borderline
Free testosterone	Upper half of lab reference (method-dependent)	Bioavailable testosterone signal	Pair with SHBG; LC-MS (liquid chromatography–mass spectrometry) preferred when available
SHBG	Mid lab range	Interprets free fraction	Rises with aging/estrogen; falls with insulin resistance
Estradiol (sensitive)	Roughly 20–40 pg/mL for many men (individualize)	Tracks testosterone-to-estrogen balance; animal data showed estradiol drop	Use sensitive (LC-MS) male assay
LH	Low–mid reference if a primary testicular-failure pattern is absent	Confirms pituitary drive if testosterone rises	Suppressed LH with high testosterone suggests outside androgens or product tampering
FSH	Lab reference	Sperm-production axis context	Less central to libido claims than LH/testosterone
ALT	Often aimed <30 U/L functional	Liver-cell injury screen	Conventional upper limit often ~40–55 U/L, higher than the functional target; fasting not required; compare to personal baseline
AST	Often aimed <30 U/L functional	Liver-cell injury screen	Conventional upper limit often ~40–50 U/L; also muscle-derived after hard training
GGT	Low–mid reference; functional preference toward lower	Bile-flow, alcohol, or other liver-stress signals	Useful add-on when ALP moves
ALP	Lab reference	Bile-duct or bone enzyme forms	Small rise seen in human safety arm; stay in range
Total bilirubin	Lab reference	Liver clearance function	Rising with enzymes warrants stop
Creatinine / eGFR	eGFR ≥90 mL/min/1.73 m² preferred; stage by KDIGO (Kidney Disease: Improving Global Outcomes criteria) if lower	Kidney filtration safety	Hydration and muscle mass affect creatinine
Fasting lipid panel	TG <100–150 mg/dL; HDL adequate for sex; LDL individualized	Animal data worsened lipids	9–12 h fast; LDL (low-density lipoprotein)
CBC (hematocrit)	Hematocrit typically <50–52% for many men on androgens	Androgen-related erythrocytosis (excess red-blood-cell mass) screen	More critical if combined with TRT

Qualitative markers:

Libido and morning erections
Training performance and recovery
Mood, irritability, and sleep quality
Skin (acne), hair shedding, breast tenderness
Right-upper-quadrant discomfort, urine color, unusual bruising

Defining success: A meaningful morning total/free testosterone rise toward agreed personal targets without ALT/AST/GGT, creatinine, or lipid deterioration and without adverse mood or pain symptoms. Absence of hormone change after a monitored 4-week course at a documented dose is a sound reason to discontinue rather than raise the dose without new data.

Emerging Research

Absence of registered efficacy trials: No ClinicalTrials.gov studies of Bulbine natalensis for testosterone, hypogonadism, or sexual function were identified (search August 2026). A future placebo-controlled human hormone trial would most change clinical confidence.
Human safety abstract needs full published reports: The Hofheins et al. 2012 Journal of the International Society of Sports Nutrition (JISSN) abstract on ProLensis™ short-term safety remains the only human clinical dataset widely cited; peer-reviewed full papers with hormone endpoints would shift the risk–benefit discussion in either direction.
Human drug-level interaction studies: Building on Husain et al. 2021 (CYP3A4/2C9) and Husain et al. 2022 (AhR, CYP1A2, CYP2B6, P-gp), human studies using standard probe drugs could confirm or downgrade drug-interaction alerts.
Independent replication of androgen endpoints: Nearly all testosterone and sexual-behavior positives come from one South African group’s rat series (Yakubu & Afolayan 2009–2010). Independent labs using standardized extracts would strengthen or weaken the efficacy claim.
Analytical standardization: Methods such as Bae et al. 2020 UHPLC quantification of anthraquinones enable lot testing; broader adoption would reduce product-to-product variability in any future trials.
Taxonomy and composition: Continued clarification of B. natalensis versus B. latifolia naming and of knipholone content across commercial lots may explain variable user reports.

Conclusion

Bulbine natalensis (synonym Bulbine latifolia) is a southern African stem extract sold for male testosterone and sexual vitality support. Controlled rat studies—mostly from one research group—show mid-range doses can raise luteinizing hormone, follicle-stimulating hormone, and both testicular and blood testosterone, improve mating behavior, and lower estradiol, while a higher dose often blunts those gains. Those testosterone-related signals have not been confirmed in human hormone trials.

Safety evidence is mixed. The same animal dose band linked to testosterone gains altered liver and kidney enzymes and tissue structure and worsened blood lipids. A small, short human study of a branded extract reported acceptable routine lab safety over four weeks but did not measure testosterone. Cell work further flags interaction potential with common drug-metabolizing enzymes and drug-export pumps.

For health- and longevity-focused adults, the present case is therefore a possible benefit that is not yet proven, paired with notable organ and interaction cautions. The evidence base supports only short-term, laboratory-monitored evaluation of hormone and organ markers rather than a proven alternative to foundational lifestyle measures or, when indicated, medically supervised hormone care. Payer reimbursement that favors prescription hormone therapy over unproven herbals may further shape which pathways receive trials and guideline attention. Product identity and contamination risk remain practical constraints on interpreting both benefit and harm.

Top - Benefits - Risks - Protocol

Bulbine natalensis to Improve Testosterone

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Raised serum and testicular testosterone (animal)

Enhanced male sexual behavior and mating success (animal)

Increased testicular mass and anabolic testicular markers (animal)

Lower circulating estradiol (animal)

Speculative 🟨

Muscle strength, body composition, or marketed anabolic physique effects

Cognitive or energy benefits secondary to androgen change

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Liver and kidney marker and tissue-structure stress (animal; human short-term labs more reassuring) ⚠️ Conflicted

Low 🟥

Adverse lipid shift (animal)

White-cell and blood-cell shifts (animal)

High-dose behavioral suppression (animal)

Herb–drug interaction via CYP enzymes and drug-export pumps (cell models)

Heavy-metal contamination of crude market material

Early pregnancy loss risk at high dose (animal)

Speculative 🟨

Aggression, acne, or testicular discomfort (anecdotal / uncontrolled report)

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion